Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
RGNX
RGNX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
RGNX News
REGENXBIO Initiates Phase IIb/III Trial for Diabetic Retinopathy
Jun 29 2026
PRnewswire
REGENXBIO Initiates Phase IIb/III Trial for Diabetic Retinopathy
Jun 29 2026
Newsfilter
FDA's Regulatory Reversal Boosts Biotech Sector
Jun 24 2026
seekingalpha
REGENXBIO Completes Dosing in RGX-202 Confirmatory Study
Jun 24 2026
PRnewswire
REGENXBIO Completes Confirmatory Study for RGX-202 Ahead of Schedule
Jun 24 2026
Newsfilter
Tenon Files S-1, Stock Surges 77.57%
Jun 23 2026
NASDAQ.COM
Regenxbio Plans to Resubmit Navsunli Application
Jun 22 2026
stocktwits
REGENXBIO Aligns with FDA for Accelerated Approval of NAVSUNLI
Jun 22 2026
PRnewswire
REGENXBIO Aligns with FDA for Accelerated Approval of NAVSUNLI
Jun 22 2026
Newsfilter
Regenxbio Shares Surge After FDA Reversal on Drug Rejection
Jun 22 2026
seekingalpha
FDA Reversal Sparks Biotech Comeback for UniQure and Peers
Jun 17 2026
seekingalpha
Multiple Companies Experience Significant Stock Price Gains
May 22 2026
NASDAQ.COM
REGENXBIO to Participate in Investor Conferences
May 18 2026
PRnewswire
REGENXBIO Q1 2026 Earnings Call Highlights
May 15 2026
seekingalpha
RGX-202 Clinical Trial Achieves Significant Success
May 14 2026
Yahoo Finance
REGENXBIO Q1 Results Fall Short of Expectations Amid FDA Concerns
May 14 2026
stocktwits
Show More News
